STING agonist-1
Based on 5 publication(s) in Google Scholar
STING agonist-1 (G10) is human-specific STING agonist that elicits antiviral activity against emerging Alphaviruses. G10 potently blocks replication of Alphavirus species Venezuelan Equine Encephalitis Virus (VEEV) with IC90 of 24.57 μM.
For research use only. We do not sell to patients.
- Purity: 99.59%
- CAS No.: 702662-50-8
- Formula: C21H16ClFN2O3S
- Molecular Weight:430.88
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
Antiviral Compound Library
HY-L027
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Protease Inhibitor Library
HY-L147
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Immunopotentiator Compound Library
HY-L172
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) STING agonist-1
More
Biological Activity
IC90: 24.57 μM (VEEV)[1]
G10 induces IFN/IRF3- but not NF-κB-dependent transcription in human fibroblasts[1].
G10 is an indirect activator of human STING-dependent phenotypes[1].
G10-mediated IRF3 activation and anti-Alphaviral activity occur independently of IPS-1/MAVS-dependent signaling[1].
STING is required for G10-mediated IRF3 activation, gene expression, and anti-Alphaviral activity[1].
G10 induces STING-dependent synthesis and secretion of bioactive interferon[1].
G10 induces innate antiviral mRNA expression in primary human cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 702662-50-8
-
Appearance Solid
-
Molecular Weight 430.88
-
Formula C21H16ClFN2O3S
-
Color White to off-white
-
SMILES
O=C(C1=CC=C(SCC(N2CC3=C(F)C=CC=C3Cl)=O)C2=C1)NCC4=CC=CO4
-
Synonyms
G10
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
-
Cancer Immunol Res
Discovery of podofilox as a potent cGAMP-STING signaling enhancer with antitumor activity. [Abstract]2023 May 3;11(5):583-599. PMID: 36921097 -
Int Immunopharmacol
Quercetin alleviates LPS-induced inflammation and immunosuppression in broiler spleen via regulating the mtDNA/cGAS/STING axis. [Abstract]2026 May 1:176:116482. PMID: 41797087 -
-
Solvent & Solubility
DMSO : 75 mg/mL (174.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.80 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3208 mL | 11.6042 mL | 23.2083 mL | 58.0208 mL |
| 5 mM | 0.4642 mL | 2.3208 mL | 4.6417 mL | 11.6042 mL | |
| 10 mM | 0.2321 mL | 1.1604 mL | 2.3208 mL | 5.8021 mL | |
| 15 mM | 0.1547 mL | 0.7736 mL | 1.5472 mL | 3.8681 mL | |
| 20 mM | 0.1160 mL | 0.5802 mL | 1.1604 mL | 2.9010 mL | |
| 25 mM | 0.0928 mL | 0.4642 mL | 0.9283 mL | 2.3208 mL | |
| 30 mM | 0.0774 mL | 0.3868 mL | 0.7736 mL | 1.9340 mL | |
| 40 mM | 0.0580 mL | 0.2901 mL | 0.5802 mL | 1.4505 mL | |
| 50 mM | 0.0464 mL | 0.2321 mL | 0.4642 mL | 1.1604 mL | |
| 60 mM | 0.0387 mL | 0.1934 mL | 0.3868 mL | 0.9670 mL | |
| 80 mM | 0.0290 mL | 0.1451 mL | 0.2901 mL | 0.7253 mL | |
| 100 mM | 0.0232 mL | 0.1160 mL | 0.2321 mL | 0.5802 mL |
STING agonist-1 Related Classifications
HY-19711 Related Classifications
Powered by Bioz